Maximize Your Impact at iMig 2025
iMig 2025, taking place October 26–28 at the Philadelphia Marriott Downtown in Pennsylvania, is one of the leading global events dedicated to advancing thoracic oncology. Organized by the International Association for the Study of Lung Cancer (IASLC), the event brings together medical researchers, clinical practitioners, biotech leaders, and decision-makers in lung cancer treatment and diagnostics.
This is a key time for companies influencing care outcomes and digital innovation in oncology—topics that will shape purchasing decisions, policy recommendations, and funding strategies. Attendees include senior oncologists, department heads, R&D executives from biopharma companies, and policymakers responsible for clinical protocol adoption.
Leveraging the enriched attendee list allows commercial and engagement teams to prioritize relevant segments and initiate strategic conversations before the event. Early outreach increases the likelihood of setting in-person meetings with decision-makers who control trial partnerships, product evaluation criteria, and technology budgets.
How Sales, Marketing and Revops Teams Can Use This Attendee List
iMig 2025 attracts influential figures responsible for research funding, procurement of diagnostic technologies, and partnership evaluations. Use Vendelux’s enriched attendee list to group contacts by specialties such as pulmonology, thoracic surgery, or immunotherapy research. This allows outreach to reflect medical priorities and align with ongoing clinical focuses.
Teams can identify and connect with C-suite executives from biopharma companies or heads of clinical innovation units exploring partnership opportunities. The attendee data enables you to pre-arrange face-to-face meetings with verified decision-makers and segment scientific contacts differently from commercial leads.
Using confirmed attendee data to tailor conversations helps position your offering within the context of their clinical pipeline or funding pathway. After the conference, follow up with outcomes-driven messaging that reaffirms the value shared on-site. This approach maximizes how to get more meetings and converts iMig’s scientific audience into business relationships through meaningful dialogue.
Timing Is Everything
iMig 2025 runs from October 26 through October 28, 2025. With just months to go, now is the optimal time to activate your sales and marketing strategy around this event. Early engagement with the enriched conference attendee list can help teams lock in meetings before executives finalize their schedules.
Vendelux enables users to filter and prioritize attendees aligned to company objectives. Whether your focus is product trials, hospital adoption, or innovation in thoracic diagnostics, reaching out ahead of time ensures you enter the conference with an aligned meeting set.
Taking action now avoids last-minute outreach and supports a coordinated presence on-site that leads to faster conversions.
What’s Included In The iMig 2025 Attendee List?
Vendelux delivers visibility into expected attendees at iMig 2025 using a combination of organizer-sourced data and proprietary insights. Teams can upload custom account lists to surface high-priority matches.
The enriched attendee list includes each individual’s first and last name, current job title, company affiliation, company website, location by city, state, and country, LinkedIn profile, verified email address, and phone number where available.
Where Is iMig 2025?
The event will be held at the Philadelphia Marriott Downtown in Philadelphia, Pennsylvania, United States.
When Is iMig 2025?
iMig 2025 is scheduled for October 26–28, 2025.
What Type Of Event Is iMig 2025?
iMig 2025 is a global scientific and medical conference focusing on thoracic oncology. The program features peer-reviewed research presentations, plenary sessions with medical experts, clinical practice updates, poster presentations, and networking sessions across academia and industry.
How Many People Attend iMig 2025?
The event typically brings together more than 1,500 participants from over 60 countries. Attendees range from oncology clinicians and surgeons to health system leaders, biopharma executives, and researchers with mid-to-senior-level decision-making responsibilities.
